AZD5582 treatment triggered latency reversal of systemic HIV and SIV and showed the potential for use of a combination treatment approach to aid in systemic clearance of persistent HIV infection in resting CD4+ T cells [60]. Here, CD4 is linked to HIV infectious disease.